AQR Capital Management
AST

AQR Capital Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

AQR Capital Management’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-50,032
Closed -$194K – 2407
2015
Q3 		$194K Buy
+50,032
New +$230K ﹤0.01% 2068

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management's AST Position: Q4 2015 in Review

AQR Capital Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2015, closing a stake of 50,032 shares — an estimated $194K sold.

AQR Capital Management first reported a position in AST in Q3 2015 and held it in 1 quarter. The position peaked at $194K in Q3 2015. 56 funds tracked by Wall St. Rank hold AST as of Q4 2015.

  • AQR Capital Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2015 after selling out during the quarter.
  • AQR Capital Management sold 50,032 Asterias Biotherapeutics Inc. Series A shares in Q4 2015, an estimated $194K.
  • AQR Capital Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q3 2015 and held it in 1 quarter.
  • AQR Capital Management's Asterias Biotherapeutics Inc. Series A position peaked at $194K in Q3 2015.
  • 56 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2015.

Based on AQR Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.